William Lowther to Mitochondria
This is a "connection" page, showing publications William Lowther has written about Mitochondria.
Connection Strength
0.796
-
Haynes AC, Qian J, Reisz JA, Furdui CM, Lowther WT. Molecular basis for the resistance of human mitochondrial 2-Cys peroxiredoxin 3 to hyperoxidation. J Biol Chem. 2013 Oct 11; 288(41):29714-23.
Score: 0.400
-
Cunniff B, Newick K, Nelson KJ, Wozniak AN, Beuschel S, Leavitt B, Bhave A, Butnor K, Koenig A, Chouchani ET, James AM, Haynes AC, Lowther WT, Murphy MP, Shukla A, Heintz NH. Disabling Mitochondrial Peroxide Metabolism via Combinatorial Targeting of Peroxiredoxin 3 as an Effective Therapeutic Approach for Malignant Mesothelioma. PLoS One. 2015; 10(5):e0127310.
Score: 0.113
-
Riedel TJ, Knight J, Murray MS, Milliner DS, Holmes RP, Lowther WT. 4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition. Biochim Biophys Acta. 2012 Oct; 1822(10):1544-52.
Score: 0.092
-
Riedel TJ, Johnson LC, Knight J, Hantgan RR, Holmes RP, Lowther WT. Structural and biochemical studies of human 4-hydroxy-2-oxoglutarate aldolase: implications for hydroxyproline metabolism in primary hyperoxaluria. PLoS One. 2011; 6(10):e26021.
Score: 0.088
-
Cox AG, Pearson AG, Pullar JM, Jönsson TJ, Lowther WT, Winterbourn CC, Hampton MB. Mitochondrial peroxiredoxin 3 is more resilient to hyperoxidation than cytoplasmic peroxiredoxins. Biochem J. 2009 Jun 12; 421(1):51-8.
Score: 0.075
-
Hill TK, Davis AL, Wheeler FB, Kelkar SS, Freund EC, Lowther WT, Kridel SJ, Mohs AM. Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines. Mol Pharm. 2016 Mar 07; 13(3):720-8.
Score: 0.030